文献速递胸部肿瘤

新型ALK抑制剂dirozalkib的临床前表征及晚期非小细胞肺癌首次人体I期试验

Preclinical characterization and first-in-human, phase I trial of the novel ALK inhibitor dirozalkib in advanced non-small cell lung cancer.
PubMed 文献 · Eur J Cancer · 2026-01-07

该研究评估了新型ALK抑制剂dirozalkib的临床前特征及在晚期NSCLC患者中的安全性、药代动力学和初步抗肿瘤活性。临床前显示其对ALK融合阳性细胞系及常见耐药突变有强效抑制,并在患者来源及颅内异种移植肺癌模型中抑制肿瘤生长。I期试验(NCT05055232)纳入114例ALK或ROS1重排的晚期NSCLC患者,未发生剂量限制性毒性,最大耐受剂量为600 mg/日,推荐的II期剂量为500 mg/日;ALKi初治患者接受500 mg/日时ORR达89.3%。

要点

  • dirozalkib临床前对ALK融合及常见耐药突变有强效抑制,颅内模型有效。
  • I期未发生DLT,MTD为600 mg/日,推荐II期剂量500 mg/日。
  • ALKi初治患者500 mg/日时ORR达89.3%,总体安全性可控。

核心结论

  • dirozalkib在晚期ALK重排NSCLC中表现出良好的安全性、抗肿瘤活性和药代动力学特征,推荐II期剂量为500 mg/日。

研究设计与样本

  • 临床前研究评估dirozalkib的体外和体内抑制效果。
  • 首次人体I期研究(NCT05055232)纳入ALK或ROS1重排的晚期NSCLC患者,采用3+3剂量递增设计(50-600 mg/日,快速滴定),扩展阶段为300-600 mg/日,主要终点为安全性。

主要发现

  • dirozalkib强效抑制ALK融合阳性细胞系和常见耐药突变,并在患者来源和颅内异种移植肺癌模型中抑制肿瘤生长。
  • 未发生剂量限制性毒性,最大耐受剂量为600 mg/日。
  • 114例患者中55例(48.2%)发生≥3级治疗中出现的不良事件,最常见为腹泻(8.8%)。
  • 剂量递增队列中ALK重排患者ORR为47.4%(9/19),剂量扩展队列为46.3%(38/82);ALKi初治患者接受500 mg/日时ORR为89.3%。
  • 单次给药50-600 mg后,中位达峰时间为3-4小时,Cmax和AUC接近剂量比例增加,几何平均终末消除半衰期为19.6-25.4小时。

关键数值与推荐

  • 推荐的II期剂量为500 mg/日。
  • 最大耐受剂量为600 mg/日。
  • ≥3级治疗中出现的不良事件发生率为48.2%(55/114),最常见为腹泻(8.8%)。
  • ALK重排患者ORR:剂量递增队列47.4%(9/19),剂量扩展队列46.3%(38/82)。
  • ALKi初治患者接受500 mg/日时ORR为89.3%。

临床怎么用

  • dirozalkib在ALK重排晚期NSCLC中具有可控的安全性和有前景的抗肿瘤活性,尤其对ALK抑制剂初治患者。
  • 推荐II期剂量为500 mg/日,需关注腹泻等不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To investigate the preclinical characterization of dirozalkib, a novel anaplastic lymphoma kinase (ALK) inhibitor, and its safety, pharmacokinetics, and preliminary antitumor activity in advanced non-small cell lung cancer (NSCLC). METHODS: The preclinical inhibitory effects of dirozalkib were evaluated in vitro and in vivo. The first-in-human phase I study (NCT05055232) enrolled patients with advanced NSCLC harboring ALK or ROS1 rearrangements. Participants received 50-600 mg/day dirozalkib following a 3 + 3 dose-escalation design with rapid titration, and 300-600 mg/day in the dose-expansion phase. The primary endpoint was safety. RESULTS: Dirozalkib demonstrated potent inhibition of ALK fusion-positive cell lines and common resistance mutations, and suppressed tumor growth in patient-derived and intracranial xenograft lung cancer models. No dose-limiting toxicities occurred, establishing 600 mg/day as the maximum tolerated dose. Among 114 patients enrolled, 55 (48.2 %) experienced grade ≥ 3 treatment-emergent adverse events, most commonly diarrhea (8.8 %). The objective response rate (ORR) among patients with ALK rearrangements was 47.4 % (9/19) and 46.3 % (38/82) in the dose-escalation and dose-expansion cohort (89.3 % in ALK inhibitor-naive patients receiving 500 mg/day). After a single dose of 50-600 mg dirozalkib, median time to maximum concentration ranged from 3 to 4 h. Cmax and area under the curve of dirozalkib increased near-dose-proportional, with a geometric mean terminal elimination half-life of 19.6-25.4 h. CONCLUSIONS: Dirozalkib exhibited favorable safety, antitumor activity and pharmacokinetics in patients with advanced ALK-rearranged NSCLC. The recommended phase II dose was 500 mg/day. TRIAL REGISTRATION: Clinicaltrials.gov (NCT05055232) and Chinadrugtrials.org.cn (CTR20190984).

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Ai X, Guo R, Zhang L, et al. Preclinical characterization and first-in-human, phase I trial of the novel ALK inhibitor dirozalkib in advanced non-small cell lung cancer. Eur J Cancer. 2026. PMID: 41539180. doi:10.1016/j.ejca.2026.116221

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。